ResMed Inc. Common Stock (NYSE:RMD):
Results from World’s Largest Study on Sleep Apnea and Digital Connected Care.
The company is now up from yesterday’s close of $59.83.
Additionally the company recently declared a dividend for shareholders paid on Thursday September 22nd, 2016. The dividend payment was $0.330 per share for the quarter which is $1.32 annualized. This dividend represents a yeild of $2.06 which is the dividend as a percentage of the current share price. The ex-dividend date was set for Tuesday the 16th of August 2016.
It is currently trading at $60.35 barely below the 50 day moving average which is $63.95 and which is just a bit below the 200 day moving average of $63.07. The 50 day moving average was down $-3.60 or -5.64% whereas the 200 day average was down by -4.32%.
The P/E ratio is currently 24.63 and the market value is 8.50B. In the latest earnings report the EPS was $2.45 and is projected to be $2.77 for the current year with 140,785,000 shares outstanding. Next quarter’s EPS is forecasted to be $0.71 and the next full year EPS is anticipated to be $3.06.
A few brokerage analysts have released opinions on the company of late. On September 29, 2016 the stock rating was rated “Buy” in a report from Bank of America which was a boost from the previous “” rating. On September 19 the stock rating was downgraded from “Overweight” to “Neutral” by JP Morgan.
On August 23 the company was set at “Underperform” according to a Jefferies report a cut from the previous “Hold” rating. On June 27 the company was downgraded to “Underperform” from “Hold” in a statement from Needham.
On April 28 the stock rating was upgraded from “Neutral” to “Neutral” and a price target of $57.00 was set by analysts at Macquarie. On April 27 the company was downgraded to “Neutral” from “” with a current price target of $57.00 in a report from Piper Jaffray.